We have previously shown that full-length SPARC and SPARC peptide FS-E, that corresponds to the highly conserved EGF-like module of the follistatin domain, potently inhibit angiogenesis and neuroblastoma tumor growth in preclinical models [10,26,30]. This evidence concerns the gene SPARC and neuroblastoma.